Lawmaker Questions FDAs Secretive Fast-Track Drug Program

A Democratic lawmaker raises concerns over an FDA program that expedites drug reviews, citing secrecy and potential ethics violations. He questions its legality and transparency, as agency staff debate the shift of decision-making from scientists.